Form 4: UroGen Pharma Director Acquires 10,000 Stock Options
SEC Form 4 Filing
A Form 4 filing reveals that UroGen Pharma Ltd. director Arie Belldegrun acquired 10,000 stock options on August 6, 2024.
Summary
- A Form 4 filing with the SEC indicates that Arie Belldegrun, a director at UroGen Pharma Ltd., acquired 10,000 stock options on August 6, 2024.
- The exercise price of these options is $15.16.
- The options vest in equal quarterly installments over one year, contingent upon the director's continuous service.
- The options expire on August 6, 2034.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing regarding stock option grants, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure related to insider transactions and provides insight into director compensation and equity ownership.
Stakeholder Impact
- The acquisition of stock options by a director aligns their interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 08/06/2024 | Date of stock option acquisition |
| 08/06/2034 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.